HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by BERRIE, C. P. Articles by FALASCA, M. Search for Related Content PubMed PubMed Citation Articles by BERRIE, C. P. Articles by FALASCA, M.

Patterns within protein/polyphosphoinositide interactions provide specific targets for therapeutic intervention¹

Department of Cell Biology and Oncology, Istituto di Ricerche Farmacologiche ‘Mario Negri’, Consorzio Mario Negri Sud, 66030 Santa Maria Imbaro (Chieti), Italy; and
^* Department of Oncology and Neuroscience, Section of Medical Oncology, University ‘G. D’Annunzio’ Medical School, 66100 Chieti, Italy

²Correspondence: Department of Cell Biology and Oncology, Istituto di Ricerche Farmacologiche ‘Mario Negri’, Consorzio Mario Negri Sud, Via Nazionale, 66030 Santa Maria Imbaro (Chieti), Italy. E-mail: berrie{at}cmns.mnegri.it

Signaling pathways involving the inositol polyphosphates and the polyphosphoinositides have become intricately linked with a number of disease states. More recently, this has principally involved the 3-phosphorylated products of phosphoinositide 3-kinase, an enzyme that itself shows oncogenic activity and has hence become of interest in the design of antitumorigenic drugs. The downstream effectors of phosphoinositide 3-kinase are involved in different aspects of cellular signaling and cytoskeleton and trafficking events that are linked to specific polyphosphoinositide binding properties of specific protein domains, which themselves have emerging roles in specific disease states. Our recent findings have demonstrated that there is a selectivity of the intracellular effects of extracellularly applied inositol polyphosphates in their abilities to inhibit a range of growth-related in vivo assay conditions, and that these can themselves be linked to the inhibition of the membrane localization of a green fluorescent protein (GFP) -tagged PH domain. We propose that GFP fusions of the polyphosphoinositides binding domains of specific proteins of interest can be used in high-throughput investigations of the therapeutic value of specific inositol polyphosphates analogs. Inhibition of in vivo membrane targeting of these domains from proteins involved in cell growth and tumorigenesis can thus be used in the search for new anticancer drugs.—Berrie, C. P., Falasca, M. Patterns within protein/polyphosphoinositide interactions provide specific targets for therapeutic intervention.

Key Words: phosphoinositide 3-kinase • polyphosphoinositides • inositol polyphosphates • PH/FYVE/HIKE domains • cancer therapy

This article has been cited by other articles:

				T. Maffucci, E. Piccolo, A. Cumashi, M. Iezzi, A. M. Riley, A. Saiardi, H. Y. Godage, C. Rossi, M. Broggini, S. Iacobelli, et al. Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects Cancer Res., September 15, 2005; 65(18): 8339 - 8349. [Abstract] [Full Text] [PDF]